TRACON Pharmaceuticals (TCON)
(Delayed Data from NSDQ)
$1.34 USD
+0.08 (6.35%)
Updated Jun 17, 2024 04:00 PM ET
After-Market: $1.33 -0.01 (-0.75%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Brokerage Reports
0 items in cart
TRACON Pharmaceuticals, Inc. [TCON]
Reports for Purchase
Showing records 41 - 60 ( 70 total )
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Protocol of the Pivotal ENVASARC Trial for Envafolimab in Sarcoma Receives Clearance From the FDA
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Results; Pivotal ENVASARC Trial IND Filed With FDA; First Patient Expected to Enroll 4Q20
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Protocol Filing With the FDA for ENVASARC Pivotal Trial Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; Envafolimab Pivotal Trial Anticipated to Start 2H20
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
TRACON Retains Global Rights to TRC253 Following Disappointing Data; Lowering PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
May 8 Teleconference With FDA to Discuss ENVASARC Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Request for Type B FDA Meeting Regarding Envafolimab Pivotal Study Submitted
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Development of DE-122 Discontinued; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q Results; Envafolimab Pivotal Study in 2H20; Lowering PT Due to Recent Capital Raises
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Potentially Transformational Deal Announced; Raising PT by $3 to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Updating Model and Price Target After 1-for-10 Reverse Stock Split
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; DE-122 Data in Wet AMD Expected 1H20
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Partnering to Success; Initiating Coverage With a Buy and $2 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap -TRC105 and TRC102 Clinical Profile Expansion Contnues
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D